Matching Placebo (B)

DIETARY_SUPPLEMENT4 trials

Sponsors

Syntara, Netherlands Heart Institute, Varol TUNALI, University of Genova

Conditions

Heart FailureMetabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic SyndromeOverweight (BMI > 25)Overweight (Without Type 2 Diabetes) With Weight-related ComorbiditiesREM Sleep Behavior Disorder

Phase 2

Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder

Active, not recruitingNCT05904717

SyntaraREM Sleep Behavior Disorder

Start: 2023-11-08End: 2026-09-30Updated: 2026-06-02

Phase 3

The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.

RecruitingNCT07234422

Netherlands Heart InstituteHeart Failure

Start: 2026-05-04End: 2030-12-01Target: 1100Updated: 2026-05-19

Unknown Phase

AIM-WEIGHT: AI-Guided Microbiome-Targeted Nutritional Intervention for Weight Loss

Enrolling by invitationNCT07736547

Varol TUNALIOverweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight (BMI > 25)

Start: 2026-08-01End: 2027-06-30Target: 80Updated: 2026-07-30

Gdue Plus a Hypocaloric Mediterranean Diet in Adults With MASLD

CompletedNCT07763626

University of GenovaMetabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Syndrome

Start: 2023-09-01End: 2025-07-31Updated: 2026-08-13